New paper demonstrates Affimers in plant virus diagnosis ELISA

Over 6% of global food production is lost due to pathogens, including plant viruses. Plant viruses in the field are often mismanaged or unmanaged due to difficulties in detection of the appropriate virus. Rapid diagnosis and containment is important to prevent disease spread and crop losses. Unfortunately, for many plant viruses this is not practical as the methods of detection are serology which depends on antibodies, many of which are not available, or nucleic acid extraction, amplification and genome sequencing. Both techniques require shipping samples to distant labs, adding time and expense to diagnosis.

Issues with antibodies in developing diagnostic tests for crops include the requirement for large amounts of target virus to develop antibodies against. In many cases obtaining such quantities of virus can be difficult or in some cases impossible and if sourced present with issues around containment in propagating wild type viruses. For these reasons, a team of researchers at the University of Leeds and their collaborators from the John Innes Centre, employed Affimer reagents in their newly published study in the journal Scientific Reports, ‘Affimer reagents as tools in diagnosing plant virus diseases (link is external)’ where they utilise Affimers in an ELISA to distinguish between infected and uninfected crude leaf extracts, that can be developed into a field-based diagnostic assay.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is